KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

Abstract:

AIM:To carry out a nationwide study of KRAS testing in metastatic colorectal cancer as reported by nine major molecular pathology service providers in Australia, including mutation frequencies and turnaround times that might impact on patient care. METHODS:Participating laboratories contributed information on KRAS mutation frequencies, including the G13D mutation type, as well as turnaround times for tumor block retrieval and testing. RESULTS:The KRAS mutation frequency observed by nine different test sites for a total of 3688 metastatic colorectal cancers ranged from 34.4% to 40.7%, with an average across all sites of 38.8%. The average frequency of the G13D mutation type among all cases was 8.0%. The median turnaround time was 17 days (range 0-191), with 20% of cases requiring more than 4 weeks for a KRAS test result. The major contributor to long turnaround times was the time taken to retrieve archived blocks of primary tumor, particularly from sources external to the test site. CONCLUSION:The frequency of KRAS mutations in metastatic colorectal cancer reported by the major Australian test sites is very similar to that reported by other large overseas studies. More widespread introduction of routine testing at the time of initial diagnosis should eliminate the long turnaround times currently being experienced in a significant proportion of cases. Future expansion of testing to include other KRAS and NRAS mutation hotspots may spur the introduction of next-generation sequencing platforms.

journal_name

Asia Pac J Clin Oncol

authors

Scott RJ,Fox SB,Desai J,Grieu F,Amanuel B,Garrett K,Harraway J,Cheetham G,Pattle N,Haddad A,Byron K,Rudzki B,Waring P,Iacopetta B

doi

10.1111/ajco.12201

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

261-5

issue

3

eissn

1743-7555

issn

1743-7563

journal_volume

10

pub_type

杂志文章
  • Prognostic value of enhancement rate by enhanced ultrasound in hepatitis B virus-positive hepatocellular carcinoma undergoing radiofrequency ablation.

    abstract:AIM:To assess the prognostic significance of enhancement rate (ER) measured by contrast-enhanced ultrasonography (CEUS) in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA). MATERIALS AND METHODS:A total of 253 patients with single primary HCC undergoing preoperative CEUS and RFA we...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13157

    authors: Zhou G,Cai ZQ,Luo J,Hu ZX,Luo H,Wu H,Chen Q

    更新日期:2019-08-01 00:00:00

  • Radiation oncology during COVID-19: Strategies to avoid compromised care.

    abstract::The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for those who are hospitalized however, is high. Resources for usual c...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1111/ajco.13456

    authors: Horsley PJ,Back M,Lamoury G,Porter B,Booth J,Eade TN

    更新日期:2021-02-01 00:00:00

  • Additional chemotherapy and salvage surgery for poor response to chemoradiotherapy in rectal cancers.

    abstract:AIM:A proportion of locally advanced rectal cancer patients who receive neoadjuvant chemoradiotherapy (NACRT) are still unresectable. This study was undertaken to assess the outcomes of giving additional chemotherapy to rectal cancer patients with unresectable disease after NACRT. METHODS:Patients with poor response t...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12660

    authors: Engineer R,Ostwal V,Arya S,Gupta P,Chopra S,Patil P,Jatal S,Saklani A

    更新日期:2017-08-01 00:00:00

  • Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival.

    abstract:AIM:Metadherin (MTDH) is a potential oncogene in tumor development and is highly expressed in various types of human cancers. However, there has been no report on the role of MTDH in bladder cancer. Our aim was to investigate the expression pattern of MTDH in bladder tissue at different clinic pathological stages and e...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2012.01541.x

    authors: Zhou J,Li J,Wang Z,Yin C,Zhang W

    更新日期:2012-09-01 00:00:00

  • Development and pilot testing of a radiation therapist-led educational intervention for breast cancer patients prior to commencing radiotherapy.

    abstract:AIM:To describe the development of the content and pilot testing of a radiation therapist-led educational intervention for breast cancer patients about to commence radiotherapy. Pilot testing consisted of testing the intervention for appropriateness, feasibility and acceptance. METHODS:A tailored intervention consisti...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1743-7563.2012.01520.x

    authors: Halkett GK,Schofield P,O'Connor M,York D,Jefford M,Jiwa M,Spry N,Taylor M,Aranda S

    更新日期:2012-09-01 00:00:00

  • Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer.

    abstract:BACKGROUND:Small cell lung cancer is a rapidly progressive disease with high fatality. No sensitive and specific biomarker to assist in managing this disease exists currently. AIM:Role of pretreatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. METHODS:A hospital-based cancer registry was us...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12674

    authors: Hsieh AH,Tahkar H,Koczwara B,Kichenadasse G,Beckmann K,Karapetis C,Sukumaran S

    更新日期:2018-04-01 00:00:00

  • A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma.

    abstract:AIM:Vascular endothelial growth facto receptor-tyrosine kinase inhibitors (VEGFR-TKIs) are widely used for metastatic renal cell carcinoma (mRCC). The aim of this study was to investigate the association between the response to VEGFR-TKIs and hyperlipidemia and hypothyroidism. METHODS:Clinical data on 155 patients wit...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12473

    authors: Song Y,Du C,Zhang W,Sun Y,Yang L,Cui C,Chi Y,Shou J,Zhou A,Wang J,Sun Y

    更新日期:2016-06-01 00:00:00

  • Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI-defined T3, T4 or N+ rectal cancer: a randomized clinical trial.

    abstract:BACKGROUND:Clinical trials investigating the effects of addition of oxaliplatin to neoadjuvant radiochemotherapy in locally advanced rectal cancers (LARCs) have brought controversial results for pathologic complete response as an endpoint. This randomized clinical trial investigated downstaging as a short-term surrogat...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/ajco.12675

    authors: Haddad P,Miraie M,Farhan F,Fazeli MS,Alikhassi A,Maddah-Safaei A,Aghili M,Kalaghchi B,Babaei M

    更新日期:2017-12-01 00:00:00

  • Effectiveness of image-guided radiotherapy for rectal cancer patients treated with neoadjuvant concurrent chemoradiotherapy: A population-based propensity score-matched analysis.

    abstract:AIM:The effects of image-guided radiotherapy (IGRT, an advanced RT technology) have been debated in the literature. We compared the outcomes of locally advanced rectal cancer (LARC) patients treated with neoadjuvant concurrent chemoradiotherapy (NCCRT; with vs without IGRT) in a large population-based propensity score ...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13196

    authors: Li CC,Liang JA,Chen WT,Chien CR

    更新日期:2019-10-01 00:00:00

  • Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.

    abstract::Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to i...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13064

    authors: Boyle F,Beith J,Burslem K,de Boer R,Hui R,Lim E,McCarthy N,Redfern A,Woodward N

    更新日期:2018-10-01 00:00:00

  • A mixed methods analysis of experiences and expectations among early-career medical oncologists in Australia.

    abstract:AIM:A viable and sustainable medical oncology profession is integral for meeting the increasing demand for quality cancer care. The aim of this study was to explore the workforce-related experiences, perceptions and career expectations of early-career medical oncologists in Australia. METHODS:A mixed-methods design, i...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12844

    authors: Wong WKT,Kirby E,Broom A,Sibbritt D,Francis K,Karapetis CS,Karikios D,Harrup R,Lwin Z

    更新日期:2018-10-01 00:00:00

  • Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

    abstract:AIM:The open-label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first-line, every-2-weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX in this patient population. METHODS:A subgroup analysis ...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13154

    authors: Price T,Shen L,Ma B,Esser R,Chen W,Gibbs P,Lim R,Cheng AL

    更新日期:2019-08-01 00:00:00

  • Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.

    abstract:AIM:Cabazitaxel is a next generation taxane that has been shown to improve overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed during or after docetaxel-based therapy. A worldwide early access program (EAP) study was established to provide access to cabazit...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12679

    authors: Parente P,Ng S,Parnis F,Guminski A,Gurney H

    更新日期:2017-12-01 00:00:00

  • Decision aids for breast and nodal surgery in patients with early breast cancer: development and a pilot study.

    abstract:AIM:As survival rates for aggressive and conservative breast and lymph node surgery are similar, surgical treatment decisions for patients with early-stage breast cancer should take patient preference into account. Decision aids have been demonstrated to increase patient knowledge and satisfaction with decision making,...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1743-7563.2010.01375.x

    authors: Harwood R,Douglas C,Clark D

    更新日期:2011-06-01 00:00:00

  • Effect of pre existing respiratory conditions on survival of lung cancer patients: A nationwide population-based cohort study.

    abstract:BACKGROUND:Common diseases with potential to increase the risk of death from lung cancer have so far not been studied in large populations. METHODS:We did a population-based retrospective cohort study using nationwide health insurance claims data from 2005 to 2012 in Korea including 205 403 lung cancer patients. Multi...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12697

    authors: Hong S,Park EC,Kim TH,Kwon JA,Yoo KB,Han KT,Yoo JW,Kim SJ

    更新日期:2018-04-01 00:00:00

  • Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.

    abstract:AIM:In colorectal cancer (CRC), adjuvant therapy is offered on the basis of stage and attempts to identify factors to better target treatment have not been successful. Recent work suggested that mismatch repair deficient CRCs may not benefit from 5FU adjuvant chemotherapy but studies remain conflicting. We aimed to det...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12411

    authors: Thomas ML,Hewett PJ,Ruszkiewicz AR,Moore JW

    更新日期:2015-12-01 00:00:00

  • Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.

    abstract:AIMS:The optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who achieved complete remission (CR) and complete consolidation chemotherapy is still controversial. Whether the use of arsenic trioxide (ATO) alone or along with all-trans retinoic acid (ATRA) improves overall survival (OS) or di...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2011.01496.x

    authors: Chiang YH,Chang YF,Hsieh RK,Lin J,Chen CG,Lim KH,Lin HC,Chang MC

    更新日期:2012-12-01 00:00:00

  • Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.

    abstract:AIMS:Quality of life (QOL) is important in patients with advanced cancer. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 is a general QOL tool used in cancer patients. Often, with a large enough sample, statistical significance of changecan be reached, however the clinical significance i...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12070

    authors: Bedard G,Zeng L,Zhang L,Lauzon N,Holden L,Tsao M,Danjoux C,Barnes E,Sahgal A,Poon M,Chow E

    更新日期:2014-06-01 00:00:00

  • Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.

    abstract:AIMS:Currently, the only standard systemic treatment for advanced hepatocellular carcinoma is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the novel combination of sorafenib and gemcitabine in the treatment of advanced hepatocellular carcinoma. METHODS:Between March 2008 and Octo...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/ajco.12191

    authors: Srimuninnimit V,Sriuranpong V,Suwanvecho S

    更新日期:2014-09-01 00:00:00

  • Attitudes of patients with metastatic cancer towards research biopsies.

    abstract:AIM:To evaluate the attitudes of patients with different cancers towards research biopsies outside a clinical trial. METHODS:Patients with metastatic cancer completed a questionnaire that assessed patients' willingness to consider research biopsies. Research biopsies were divided into two groups: biopsies performed as...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12783

    authors: Robinson DH,Churilov L,Lin NU,Lim E,Seah D

    更新日期:2018-06-01 00:00:00

  • Changes in DNA methylation after 6-week exercise training in colorectal cancer survivors: A preliminary study.

    abstract:AIM:Behavioral interventions such as exercise may induce epigenetic changes. Only few studies investigated the effects of exercise on epigenetic alterations in colorectal cancer survivors. The aim of this study was to explore the changes of genome-wide DNA methylation after 6-week exercise training in colorectal cancer...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13482

    authors: Hwang SH,Kang DW,Lee MK,Byeon JY,Park H,Park DH,Kim KC,Lee ST,Chu SH,Kim NK,Jeon JY

    更新日期:2020-10-13 00:00:00

  • National and subnational mortality of urological cancers in Iran, 1990-2015.

    abstract:PURPOSE:To study trends of urological cancers mortalities in Iran between 1990 and 2015 as a part of a larger project named national and subnational burden of diseases, injuries, and risk factors. METHODS:The primary dataset of this project comprises data of national death registration system. Cause-specific mortality...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 历史文章,杂志文章

    doi:10.1111/ajco.13074

    authors: Pishgar F,Amini E,Gohari K,Aminorroaya A,Sheidaei A,Rostamabadi Y,Ebrahimi H,Yoosefi M,Naderimagham S,Rezaei N,Modirian M,Namazi Shabestari A,Kompani F,Farzadfar F

    更新日期:2019-04-01 00:00:00

  • Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change.

    abstract:AIM:Multidisciplinary care is advocated as best practice in cancer care. Relatively little is documented about multidisciplinary team (MDT) meeting functioning, decision making and the use of evidence to support decision making in Australia. This descriptive study aimed to examine team functioning, the role of team mee...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12765

    authors: Rankin NM,Lai M,Miller D,Beale P,Spigelman A,Prest G,Turley K,Simes J

    更新日期:2018-02-01 00:00:00

  • Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy.

    abstract:AIM:The effect of transcatheter arterial chemoembolization (TACE) therapy on hepatitis B virus (HBV) reactivation in hepatocellular carcinoma (HCC) patients with prior resolved hepatitis B is not fully understood. METHODS:From January 2006 to December 2010, 43 hepatitis B surface antigen (HBsAg)-negative/anti-hepatiti...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2012.01534.x

    authors: Peng JW,Lin GN,Xiao JJ,Jiang XM

    更新日期:2012-12-01 00:00:00

  • An exploration of the dynamics and influences upon second medical opinion consultations in cancer care.

    abstract:AIM:The aim of this study was to explore the dynamics within second medical opinion consultations in patients with cancer. METHODS:Semi-structured interviews were held with four oncologists and were subjected to a thematic analysis to define the broad issues. These formed the basis of a survey distributed to Australia...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2010.01330.x

    authors: Philip J,Gold M,Schwarz M,Komesaroff P

    更新日期:2011-03-01 00:00:00

  • Cancer in Pregnancy.

    abstract::Cancer in pregnancy may be increasing in incidence with advancing maternal age and higher rates of obesity. The diagnosis of cancer in pregnancy provokes complex management issues balancing short- and long-term risks for both mother and baby. Every case needs to be individualized, with a multidisciplinary team of midw...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1111/ajco.13235

    authors: Eastwood-Wilshere N,Turner J,Oliveira N,Morton A

    更新日期:2019-12-01 00:00:00

  • Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.

    abstract:BACKGROUND:Azacitidine safety and efficacy were established in studies of mainly Caucasian patients. Differences in drug metabolism enzymes between Caucasian and East Asian populations prevent extrapolation of drug effects between these groups. This phase 2 study evaluated azacitidine safety, efficacy and pharmacokinet...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/ajco.12835

    authors: Du X,Lai YY,Xiao Z,Liu T,Hu Y,Sun A,Li X,Shen ZX,Jin J,Yu L,Laille E,Dong Q,Songer S,Beach CL

    更新日期:2018-06-01 00:00:00

  • Examining clinicians' perceptions of head and neck cancer (HNC) information.

    abstract:BACKGROUND:Providing appropriate educational resources to patients with head and neck cancer (HNC) is important but challenging. The aim of this study was to determine Australian clinicians' perceptions of currently used HNC information resources. METHODS:A purpose-designed questionnaire was disseminated electronicall...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12858

    authors: Jabbour J,Wykes J,Milross C,Sundaresan P,Ebrahimi A,Shepherd HL,Dhillon HM,Clark JR

    更新日期:2018-10-01 00:00:00

  • The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.

    abstract:AIM:To evaluate predictive factors which associated with oncological outcomes to first-line axitinib for metastatic renal cell carcinoma (mRCC). METHODS:A retrospective chart review was conducted patients who had been treated with axitinib as first-line therapy for the treatment of mRCC from September 2013 to February...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13323

    authors: Kameda T,Takayama T,Sugihara T,Takeshima S,Yamazaki M,Komatsubara M,Kamei J,Fujisaki A,Ando S,Kurokawa S,Fujimura T

    更新日期:2020-08-01 00:00:00

  • Oral cyclophosphamide in recurrent ovarian cancer.

    abstract:AIMS:Cyclophosphamide was widely used as a single agent prior to the advent of platinum-based regimens for epithelial ovarian cancer, and, in combination with platinum, prior to the adoption of platinum and paclitaxel as standard first-line therapy. As cyclophosphamide currently has no defined role in ovarian cancer we...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12074

    authors: Handolias D,Quinn M,Foo S,Mileshkin L,Grant P,Dutu G,Rischin D

    更新日期:2016-03-01 00:00:00